Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
European Radiology
Erschienen in: European Radiology 4/2015

01.04.2015 | Breast

Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes

verfasst von: Jin You Kim, Suck Hong Lee, Suk Kim, Taewoo Kang, Young Tae Bae

Erschienen in: European Radiology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To evaluate the association between tumour FDG uptake on preoperative PET/CT and axillary lymph node metastasis (ALNM) according to breast cancer subtype.

Methods

The records of 671 patients with invasive breast cancer who underwent 18 F-FDG PET/CT and surgery were reviewed. Using immunohistochemistry, tumours were divided into three subtypes: oestrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative, HER2-positive, and triple-negative. Tumour FDG uptake, expressed as maximum standardized uptake value (SUVmax), and clinicopathological variables were analysed.

Results

ALNM was present in 187 of 461 ER-positive/HER2-negative, 54 of 97 HER2-positive, and 38 of 113 triple-negative tumours. On multivariate analysis, high tumour SUVmax (≥4.25) (P < 0.001), large tumour size (>2 cm) (P = 0.003) and presence of lymphovascular invasion (P < 0.001) were independent variables associated with ALNM. On subset analyses, tumour SUVmax maintained independent significance for predicting ALNM in ER-positive/HER2-negative (adjusted odds ratio: 3.277, P < 0.001) and HER2-positive tumours (adjusted odds ratio: 14.637, P = 0.004). No association was found for triple-negative tumours (P = 0.161).

Conclusions

Tumour SUVmax may be an independent prognostic factor for ALNM in patients with invasive breast cancer, especially in ER-positive/HER2-negative and HER2-positive subtypes, but not in those with triple-negative subtype.

Key points

• Tumour SUVmax could be an imaging biomarker for predicting ALNM
• Tumour SUVmax predicting ALNM is effective in ER-positive/HER2-negative and HER2-positive subtypes
• Tumour SUVmax predicting ALNM is inaccurate in triple-negative subtypes
• Accurate prognostic prediction based on molecular subtype may facilitate individualized management
Literatur
1.
Weiss RB, Woolf SH, Demakos E et al (2003) Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the cancer and leukemia group B. J Clin Oncol 21:1825–1835CrossRefPubMed
2.
Arriagada R, Le MG, Dunant A, Tubiana M, Contesso G (2006) Twenty‐five years of follow‐up in patients with operable breast carcinoma. Cancer 106:743–750CrossRefPubMed
3.
Colleoni M, Rotmensz N, Maisonneuve P et al (2007) Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann Oncol 18:1632–1640CrossRefPubMed
4.
Viale G, Zurrida S, Maiorano E et al (2005) Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer 103:492–500CrossRefPubMed
5.
Yoshihara E, Smeets A, Laenen A et al (2013) Predictors of axillary lymph node metastases in early breast cancer and their applicability in clinical practice. Breast 22:357–361CrossRefPubMed
6.
Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA 295:2492–2502CrossRefPubMed
7.
Van’t Veer LJ, Dai H, De Vijver V et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536CrossRef
8.
Nguyen PL, Taghian AG, Katz MS et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373–2378CrossRefPubMed
9.
Desmedt C, Haibe-Kains B, Wirapati P et al (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158–5165CrossRefPubMed
10.
Sánchez-Muñoz A, García-Tapiador AM, Martínez-Ortega E et al (2008) Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Transl Oncol 10:646–653CrossRefPubMed
11.
de Ronde JJ, Hannemann J, Halfwerk H et al (2010) Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 119:119–126CrossRefPubMed
12.
Fuster D, Duch J, Paredes P et al (2008) Preoperative staging of large primary breast cancer with [18 F] fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 26:4746–4751CrossRefPubMed
13.
Eubank WB, Mankoff D, Bhattacharya M et al (2004) Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol 183:479–486CrossRefPubMed
14.
Hatt M, Groheux D, Martineau A et al (2013) Comparison between 18 F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med 54:341–349CrossRefPubMed
15.
Song B, Hong CM, Lee HJ et al (2011) Prognostic value of primary tumor uptake on F-18 FDG PET/CT in patients with invasive ductal breast cancer. Nucl Med Mol Imaging 45:117–124CrossRefPubMedCentralPubMed
16.
Ueda S, Tsuda H, Asakawa H et al (2008) Clinicopathological and prognostic relevance of uptake level using 18 F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18 F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 38:250–258CrossRefPubMed
17.
Koo HR, Park JS, Kang KW et al (2014) 18 F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes. Eur Radiol 24:610–618CrossRefPubMed
18.
Greene FL (2002) AJCC cancer staging manual. Springer
19.
Elston C, Ellis I (1991) Pathological prognostic factors in breast cancer. I. the value of histological grade in breast cancer: experience from a large study with long‐term follow‐up. Histopathology 19:403–410CrossRefPubMed
20.
Allred DC, Harvey JM, Berardo M, Clark GM (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed
21.
Moeder CB, Giltnane JM, Harigopal M et al (2007) Quantitative justification of the change from 10 % to 30 % for human epidermal growth factor receptor 2 scoring in the american society of clinical oncology/college of american pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol 25:5418–5425CrossRefPubMed
22.
Yamashita H, Toyama T, Nishio M et al (2006) p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res 8:R48CrossRefPubMedCentralPubMed
23.
Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750CrossRefPubMedCentralPubMed
24.
Bader AA, Tio J, Petru E et al (2002) T1 breast cancer: identification of patients at low risk of axillary lymph node metastases. Breast Cancer Res Treat 76:11–17CrossRefPubMed
25.
Ridriguez-Pinilla SM, Sarrio D, Honrado E et al (2006) Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast cancers. Clin Cancer Res 12:1533–1539CrossRef
26.
Krag DN, Anderson SJ, Julian TB et al (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8:881–888CrossRefPubMed
27.
McMasters KM, Tuttle TM, Carlson DJ et al (2000) Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol 18:2560–2566PubMed
28.
Wilke LG, McCall LM, Posther KE et al (2006) Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 13:491–500CrossRefPubMed
29.
Valente SA, Levine GM, Silverstein MJ et al (2012) Accuracy of predicting axillary lymph node positivity by physical examination, mammography, ultrasonography, and magnetic resonance imaging. Ann Surg Oncol 19:1825–1830CrossRefPubMed
30.
Kim J, Lee J, Chang E et al (2009) Selective sentinel node plus additional non-sentinel node biopsy based on an FDG-PET/CT scan in early breast cancer patients: single institutional experience. World J Surg 33:943–949CrossRefPubMed
31.
Veronesi U, De Cicco C, Galimberti VE et al (2007) A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastasis. Ann Oncol 18:473–478CrossRefPubMed
32.
Gil-Rendo A, Zornoza G, Garcia-Velloso MJ et al (2006) Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 93:707–712CrossRefPubMed
33.
Fletcher JW, Djulbegovic B, Soares HP et al (2008) Recommendations on the use of 18 F-FDG PET in oncology. J Nucl Med 49:480–508CrossRefPubMed
34.
Groves AM, Shastry M, Rodriguez-Justo M et al (2011) 18 F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Eur J Nucl Med Mol Imaging 38:46–52CrossRefPubMed
35.
Song BI, Lee SW, Jeong SY et al (2012) 18 F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer. J Nucl Med 53:1337–1344CrossRefPubMed
36.
Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334
37.
Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434CrossRefPubMed
38.
Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684–1691CrossRefPubMed
39.
Vicente AMG, Castrejón ÁS, Martín AL et al (2013) Molecular subtypes of breast cancer: metabolic correlation with 18 F-FDG PET/CT. Eur J Nucl Med Mol Imaging 40:1304–1311CrossRef
40.
Hugh J, Hanson J, Cheang MC et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168–1176CrossRefPubMedCentralPubMed
41.
Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK (1999) Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 17:2334–2340PubMed
Metadaten
Titel
Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes
verfasst von
Jin You Kim
Suck Hong Lee
Suk Kim
Taewoo Kang
Young Tae Bae
Publikationsdatum
01.04.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 4/2015
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-014-3452-y

Weitere Artikel der Ausgabe 4/2015

European Radiology 4/2015 Zur Ausgabe

Cardiac

Coronary CT angiography-derived fractional flow reserve correlated with invasive fractional flow reserve measurements – initial experience with a novel physician-driven algorithm

Magnetic Resonance

Influence of field strength, coil type and image resolution on assessment of synovitis by unenhanced MRI – a comparison with contrast-enhanced MRI

Musculoskeletal

Diagnostic performance of CT-arthrography and 1.5T MR-arthrography for the assessment of glenohumeral joint cartilage: a comparative study with arthroscopic correlation

Head and Neck

Radiological assessment of the inferior alveolar artery course in human corpse mandibles

Cardiac

Extent of late gadolinium enhancement at right ventricular insertion points in patients with hypertrophic cardiomyopathy: relation with diastolic dysfunction

Computed Tomography

Interscan variation of semi-automated volumetry of subsolid pulmonary nodules

Neu im Fachgebiet Radiologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise